Member of the Financial Accounting Standards Foundation
Disclaimer: This is a Japanese-English translation of the summary of financial statements of the Company produced for your convenience. Since no auditor audited this report, officially only the Japanese version is assumed to be the summary of financial statements of the Company. This summary does not constitute any guarantee and the Company will not compensate any losses and/or damage stemming from actions taken based on these statements. Should there be any discrepancy between the Japanese and English versions, the Japanese version is assumed to be correct.
August 11, 2021
CONSOLIDATED EARNINGS REPORT | ||
FOR THE FIRST QUARTER OF FISCAL 2021 | ||
[Japanese GAAP] | ||
Company Name: | BML, Inc. | |
Stock Listing: | Tokyo Stock Exchange | |
Stock Code: | 4694 | |
URL: | http://www.bml.co.jp/ | |
Representative: | Kensuke Kondo, President and Representative Director | |
Contact: | Norihisa Takebe, Managing Executive Officer | |
Tel: +81-3-3350-0111 | ||
Scheduled Date for Filing of Quarterly Report: | August 13, 2021 | |
Scheduled Date for Payment of Dividends: | - | |
Creation of Supplementary Explanatory Materials: | None | |
Holding of Explanatory Meeting: | None |
(Rounded down to nearest million yen)
1. Results for the First Quarter of Fiscal 2021 (April 1, 2021-June 30, 2021)
(1) Consolidated business results
(% indicates year-on-year changes) | ||||||||
Net sales | Operating income | Ordinary income | Profit attributable to | |||||
owners of parent | ||||||||
¥ million | % | ¥ million | % | ¥ million | % | ¥ million | % | |
1Q of FY2021 | 47,092 | 80.4 | 14,052 | - | 14,870 | - | 9,937 | - |
1Q of FY2020 | 26,109 | (15.3) | (108) | - | 17 | (99.5) | 111 | (94.8) |
(Note) Comprehensive income: 1Q of FY2021 | ¥10,096 million / -% | 1Q of FY2020 ¥(149) million / -% | |||
Profit attributable to | Profit attributable to | ||||
owners of parent per share | owners of parent per share (diluted) | ||||
Yen | Yen | ||||
1Q of FY2021 | 244.47 | 244.27 | |||
1Q of FY2020 | 2.74 | 2.74 |
1
(2) Consolidated financial position
Total assets | Net assets | Equity ratio | |||||||||||||
¥ million | ¥ million | % | |||||||||||||
As of June 30, 2021 | 146,323 | 101,035 | 65.8 | ||||||||||||
As of March 31, 2021 | 139,174 | 93,123 | 63.5 | ||||||||||||
(Reference) Equity capital: As of June 30, 2021 ¥96,229 million | As of March 31, 2021 | ¥88,377 million | |||||||||||||
2. Dividends | |||||||||||||||
Dividends per share | |||||||||||||||
First quarter- | Second quarter- | Third quarter- | Year-end | Full year | |||||||||||
end | end | end | |||||||||||||
Yen | Yen | Yen | Yen | Yen | |||||||||||
FY2020 | ― | 20.00 | ― | 50.00 | 70.00 | ||||||||||
FY2021 | ― | ||||||||||||||
FY2021 | 35.00 | ― | 35.00 | 70.00 | |||||||||||
(forecast) | |||||||||||||||
(Note) Revision of dividend projection from recently announced figures: None |
3. Consolidated Cumulative Earnings Forecast for the Fiscal Year Ending March 31, 2022 (April 1, 2021-March 31, 2022)
(% | indicates | year-on-year changes) | ||||||||
Profit | ||||||||||
Profit attributable | attributable | |||||||||
Net Sales | Operating income | Ordinary income | to owners of | |||||||
to owners of parent | ||||||||||
parent per | ||||||||||
share | ||||||||||
¥ million | % | ¥ million | % | ¥ million | % | ¥ million | % | Yen | ||
Full year | 154,000 | 11.1 | 32,000 | 60.5 | 33,100 | 59.1 | 20,900 | 52.4 | 514.07 | |
(Note) Revision from recently projected results: Yes
2
* Notes
(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries due to changes in the scope of consolidation): None
Increases: - | Decreases: - |
- Adoption of specific accounting methods in preparing quarterly financial statements: None
- Changes in accounting policies and changes or revisions in accounting estimates
- Changes in accounting policies in conjunction with revisions to accounting standards: Yes
- Other changes: None
- Changes in accounting estimates: None
- Restatements: None
-
Number of outstanding stocks (common stock)
a. Number of outstanding stocks at the end of the period (treasury stocks included)
As of June 30, 2021 | 44,014,726 | As of March 31, 2021 | 44,014,726 | |
b. Number of treasury stocks at the end of the period | ||||
As of June 30, 2021 | 3,367,662 | As of March 31, 2021 | 3,367,662 | |
c. Average number of shares during the period | ||||
1Q ended June 30, 2021 | 40,647,064 | 1Q ended June 30, 2020 | 40,623,492 | |
- The quarterly financial results are not subject to quarterly review by a certified public accountant or an audit firm.
- Disclaimer regarding appropriate use of forecasts and related points of note
Earnings forecasts contained in these materials are based on certain assumptions judged to be reasonable, and on the information available when the forecasts were made. However, the Company makes no guarantee that these forecasts will be achieved. Actual results may differ significantly from the forecasts due to a variety of factors. Please refer to "(3) Consolidated earnings forecasts and others" under "1. Qualitative information on operating results for quarter under review" on page 5 of this earnings report concerning financial forecasts such as the assumptions used for financial forecasts, factors that could cause these assumptions to change, and cautionary notes.
3
1. Qualitative information on operating results for quarter under review
- Operating results
In the first quarter of the consolidated fiscal year under review, the Japanese economy continued to face the profound impact of the COVID-19 pandemic, and the outlook remained uncertain as the government declared a state of emergency during which people were requested to refrain from going out and certain businesses were asked to close temporarily, thereby imposing restrictions on personal consumption and corporate activities.
Under these circumstances, the contract clinical testing business was confronted with a lackluster trend in the number of patients due to COVID-19 but also saw an expanding market amidst growth in demand for novel coronavirus-related testing. Still, the business environment remained challenging as operating activity restriction and competition with peer companies continued.
In these conditions, net sales for the first quarter of the fiscal year under review were ¥47,092 million, an increase of 80.4% year on year, and operating income was ¥14,052 million, compared with an operating loss of ¥108 million in the same period of the previous fiscal year. Ordinary income was ¥14,870 million (¥17 million in the same period of the previous fiscal year), and profit attributable to owners of parent was ¥9,937 million (¥111 million in the same period of the previous fiscal year). The large increases the BML Group achieved in both net sales and incomes reflected a solid trend in coronavirus-related testing as well as a rebound from the situation of a year earlier when people had refrained from seeking medical care due to COVID-19 concerns.
Conditions by business segment are described below.
In the clinical testing business, the BML Group made efforts in new customer acquisition, and sought to enhance business performance by implementing marketing activities to further cultivate sales of new testing items, unique testing items, priority testing items, and others. With a solid trend in coronavirus- related testing, net sales in the clinical testing business increased by 86.0% year on year. With respect to coronavirus-related testing, the Group will continue to reinforce its testing system, including genomic analysis, in order to be able to continue responding to various changes in the situation.
In the food hygiene business, the continued impact of the COVID-19 pandemic, such as customers voluntarily restricting their operations, led to a severe situation notably in the areas of food consulting and intestinal bacteria testing. Nonetheless, with some signs of a rebound from previous-year levels, net sales increased by 30.5% year on year.
As a result of the above, net sales in the testing business overall increased 84.4% year on year.
In the medical informatics business, despite restrictions on sales activities, a gradual improvement in the situation led to an increase in net sales by 8.3% year on year. With respect to the cloud-based electronic patent chart system, release is scheduled for April 2022.
In other businesses, the dispensing pharmacy business was affected by a revision of medical service fees (reduction in drug prices), but net sales recorded an increase of 4.4% year on year reflecting a rebound in the number of outpatient visits from last year's decline caused by the spread of COVID-19.
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
BML Inc. published this content on 11 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 August 2021 07:03:07 UTC.